Burney Co. Buys 4,791 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Burney Co. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 22.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 25,738 shares of the biopharmaceutical company's stock after acquiring an additional 4,791 shares during the period. Burney Co.'s holdings in Alnylam Pharmaceuticals were worth $6,056,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in ALNY. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $26,000. Huntington National Bank grew its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $42,000. Finally, True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 153 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares of the company's stock, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ALNY shares. Royal Bank of Canada reissued an "outperform" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. StockNews.com cut shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. Bank of America raised their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Barclays boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Finally, TD Cowen upped their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $298.61.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $10.50 during trading hours on Wednesday, hitting $251.01. 870,411 shares of the stock were exchanged, compared to its average volume of 688,413. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm has a market capitalization of $32.38 billion, a P/E ratio of -95.81 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a 50-day simple moving average of $248.15 and a two-hundred day simple moving average of $259.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. During the same quarter in the previous year, the company posted $1.15 EPS. The firm's revenue was down 33.3% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.